Overview

Procrit Versus No Procrit in Acute Lymphocytic Leukemia, Lymphoblastic Lymphoma, or Burkitt's Undergoing Induction/Consolidation Chemotherapy

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if Procrit (epoetin alfa) will decrease the need for blood transfusions in patients with Acute Lymphocytic Leukemia (ALL), Lymphoblastic Lymphoma (LL), or Burkitt's who are receiving chemotherapy. Another goal is to study the remission rates in patients with cancer who have received treatment with epoetin alfa.

Phase:

N/A

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Treatments:

Epoetin Alfa